Long term survival of patient with invasive aspergillosis involving orbit, paranasal sinus, and central nervous system

Aspergillus infections of the paranasal sinuses are classified as invasive or non-invasive. The vast majority are non-invasive with a good prognosis; however, the invasive type behaves as a malignant neoplasm with bone destruction, orbital and intracranial extensions, and a high mortality rate.

We present one patient with invasive paranasal aspergillosis that extended into the orbit and cranial cavities, and who has survived for 9 years and 1 month.

Case report
Along with headaches and periorbital pain beginning in July 1993, a 64 year old woman noticed a decrease vision in her right eye and visited us on 7 September 1993. She had poorly controlled diabetes mellitus. Her corrected visual acuity was 20/30 right eye and 20/20 left eye, and her critical flicker fusion examination was negative for retinal dysfunction. A central scotoma with a relative afferent papillary defect was present in the right eye. The right optic disc was slightly swollen.

A computed tomographic scan disclosed a mass in the right posterior ethmoid and sphenoid sinuses with destruction of the lateral wall of the sphenoidal sinus and the enlargement of the superior orbital fissure. The mass extended to the right orbital apex and the right cavernous sinus. Magnetic resonance imaging showed an enhanced mass, isointense on T1weighted and isointense and partially hypointense on T2weighted images (Fig 1).

Endoscopic right sphenoidectomy was performed on 18 September, and Aspergillus was histopathologically identified in a small mass isolated from the sphenoid sinus mucosa (Fig 2). Intravenous fluconazole (400–800 mg/day), oral fluclotocine (8000 mg/day), and daily transnasal sinus irrigation with amphotericin B were started on 22 September. However, she lost all vision in her right eye on 4 October.

She was transferred to the department of neurological surgery on 13 October. Antifungal therapy was continued with the addition of oral itraconazole (200 mg/day). Carotid angiography demonstrated that stenosis of the right ophthalmic artery. A frontal craniotomy was performed on 1 November, and a fibrous granulomatous lesion was found in the right posterior ethmoid sinus, sphenoid sinus, cavernous sinus, and orbit that extended to the right optic nerve. The orbit was necrotic and the sphenoid sinus was severely eroded. Cultures and histopathological examinations were negative for Aspergillus.

Histopathological section of mass obtained from the right sphenoid sinus exhibiting Aspergillus with broad, separate, and branching hyphae (Grocott-Gomori methenamine-silver stain, ×200).

The patient underwent debridement and removal of the frontal bone on 24 December because of the development of an epidural abscess. In February 1994, the abscess had extended from the right cavernous sinus to the temporal lobe and bacterial cultures were positive for Pseudomonas aeruginosa. The abscess subsided but still persisted following antibiotics and antifungal therapy.

On 13 September 1994, orbital exenteration, intracranial exenteration, and skin plasty were performed. Her diabetes mellitus is fairly well controlled by insulin injection and she has been free of aspergillosis for 9 years and 1 month after the initial presentation.

Comment
To the best of our knowledge, survival for more than 9 years of a patient with invasive paranasal aspergillosis has not been reported. The longest previous case of invasive paranasal aspergillosis is for 8 years and 2 months.

The prognosis of this disease depends on the location and the duration of the infection, and patient’s immunological status. Sphenoidal aspergillosis is aggressive nature because of the close relation to the skull base. Her poorly controlled diabetes mellitus could be a risk factor for the onset of Aspergillus infection; however, at present it is fairly controlled, presumably contributing to this long survival.

The sphenoid sinus mucosa was positive for Aspergillus but it was not found at the time of the intracranial surgery probably because of the extensive antifungal therapy before surgery and/or the low viability of the mycelium in a fungus ball.

The long term survival of this patient with orbital-paranasal aspergillosis despite intracranial extension is attributed to early diagnosis, optimal antifungal therapy, complete surgical debridement, and the improvement in the patient’s systemic condition.

K Kusaka
Division of Ophthalmology, Matsuyma Red Cross Hospital, Bunkyocho 1, Matsuyma City, Ehime 790-0826, Japan
I Shimamura, Y Ohashi
Department of Ophthalmology, Ehime University School of Medicine, Shizugawa, Shigenobuchi, Onsen-gun, Ehime 791-0295, Japan

Figure 1 (Top left) A computed tomographic scan shows a mass in the right ethmoid and sphenoid sinuses extending to the right orbital apex and the right cavernous sinus. (Top right) Coronal section shows bony destruction of the sphenoidal lateral wall. (Bottom left) Magnetic resonance imaging reveals the enhanced mass involving the right cavernous sinus and orbital apex on T1weighted, with gadolinium contrast images. (Bottom right) Magnetic resonance imaging demonstrates isointense and partially hypointense on T1weighted images.
The effect of topical glaucoma medications evaluated by perimetry

The emphasis of treatment for glaucoma has been the reduction of intraocular pressure (IOP) to a safer level, which, in turn, theoretically would prevent further visual loss. It has been assumed that lowering IOP by medical means would have an adverse effect, which could negate the beneficial effect of IOP reduction. However, several reports have raised the possibility that some may adversely affect visual function. 1 In several studies levobunolol and timolol were compared with respect to their effect on IOP reduction and perimetric findings. 2,3 Although timolol lowered IOP more effectively, betaxolol was more effective in preserving the visual field.

These findings suggest that IOP reduction is not the only parameter that demands attention. In this study, we attempted to evaluate various topical antiglaucoma medications in a normal population in terms of their short-term effect on visual function; only minimal effects on IOP reduction were expected since this study population did not have glaucoma.

Methods

Five prospective, randomised, masked studies of levobunolol, dipivefrin, apraclonidine, betaxolol, and dorzolamide, respectively, were conducted over 5 years. In each study, 20 normal volunteers had baseline testing, including measurement of visual acuity (VA), IOP visual field (VF) with the Humphrey computerised perimetry instrument (HCP) program 24-2, and pupil size. One eye was randomly assigned to treatment and given a test dose of either a glaucoma medication or a placebo. VF testing was repeated in 1 hour. The same eye was later treated with the study medication or a placebo if the drug was used and given a test dose of either a placebo if the drug was used or a placebo if the drug was used). The same eye was later treated with the study medication or a placebo if the drug was used (Table 1). There were no significant differences in terms of other global values (short-term fluctuation, pattern standard deviation, and corrected pattern standard deviation), visual acuity, and pupil size. Thus, in a normal population, a single dose of several topical glaucoma medications had little or no effect on perimetry. The possible mild suppression of retinal sensitivity with levobunolol is of unknown clinical significance.

The mechanism by which various topical glaucoma medications affect retinal sensitivity remains unclear. The effect may be due to changes in blood flow to the posterior segment of eye. Further study is needed.

Table 1  Effects of topical glaucoma medications on automated perimetry

<table>
<thead>
<tr>
<th>Medication</th>
<th>MD (dB)</th>
<th>C/W placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipivefrin</td>
<td>0.86</td>
<td>-1.05</td>
</tr>
<tr>
<td>Apraclonidine</td>
<td>-0.44</td>
<td>-0.64</td>
</tr>
<tr>
<td>Levobunolol</td>
<td>2.90</td>
<td>-1.90*</td>
</tr>
<tr>
<td>Betaxolol</td>
<td>-1.23</td>
<td>-0.79</td>
</tr>
<tr>
<td>Dorzolamide</td>
<td>+0.16</td>
<td>+0.12</td>
</tr>
</tbody>
</table>

* p < 0.05.

References

1. Hora JF. Primary aspergillosis of the paranasal sinuses and associated areas. The Laryngoscope 1965; 75:768–73.

Delayed therapeutic success with endoscopic cyclophotocoagulation in treating refractory post-penetrating keratoplasty glaucoma

Endoscopic cyclophotocoagulation (ECP) was introduced as an alternative to trans-scleral cyclophotocoagulation for treating refractory glaucomas in order to minimise complications such as phthisis and hypotony by providing direct visualisation of the ciliary processes. Commonly following penetrating keratoplasty, which has an incidence ranging from 10–52%, often proves refractory to medical treatment. 2,3 We introduce a case of refractory post-PK glaucoma in order to demonstrate the efficacy of ECP in achieving effect, post-PK glaucoma and to describe its potential delayed effect in achieving intraocular pressure control.

Case report

A 50 year old African-American man, who had undergone previous cataract surgery, anterior vitrectomy, and anterior chamber intraocular lens placement in his left eye in 1987, presented with pseudophakic bullous keratopathy and hand movement vision in his left eye. In April of 2000, the patient underwent a penetrating keratoplasty in which an 8 mm donor graft was placed in a 7.5 mm host site. Two weeks following the procedure, the patient developed elevated intraocular pressure in the 45–50 mm Hg range which was refractory to both medical therapy and discontinuation of topical steroids. An Ahmed valve was placed in June of 2000, yet his intraocular pressure eventually returned to the preoperative range despite the addition of four topical glaucoma medications (timolol 0.5%, brimonidine 0.2%, dorzolamide 2.0%, and latanoprost 0.005%). In April of 2001, the patient underwent treatment with endoscopic cyclophotocoagulation via a limbal approach as described by

S Ota
Department of Neurological Surgery, Ehime University School of Medicine, Shizu-gawa, Shigenobu-cho, Onsen-gun, Ehime 791-0295, Japan

Correspondence to: Kanae Kusaka, MD, PhD, Tane Memorial Eye Hospital, 1-1-39, Sakaigawa, Nishiku, Osaka 5500024, Japan; kkusaka@tct.zaq.ne.jp

Accepted for publication 2 October 2002

References


Chen et al. The patient received 300 degrees of treatment at settings ranging from 20–30 mW of energy with laser applied for 0.5–2 seconds until ciliary process whitening and contraction was observed (Fig 1).

During the first postoperative week, the patient was treated with topical polymyxin B/trimethoprim drops four times a day, and hyoscine (scopolamine) 0.25% drops three times a day. He was also treated with topical atropine 1% four times per day, and instillation of dexamethasone 2% drops three times a day. Despite being restarted on all four of his glaucoma medications within 3 months of each other.

Simultaneous presentation of choroidal melanoma in mother and daughter

Despite being the most common primary intraocular malignancy, uveal melanoma is rare, with an incidence of only eight per million per year. Familial cases account for only 0.6% of patients. We report two members of the same family who were both independently found to have choroidal melanoma on the same day.

Case 1

A healthy 45 year old woman presented to her general practitioner with a 1 month history of photopsia and visual field defect. She was found to have a choroidal melanoma in the right eye and referred to a general ophthalmologist, who saw her on 11 November 1999. The diagnosis of choroidal melanoma was confirmed and she was referred to our clinic, where she was seen on 22 November 1999. At our clinic the visual acuity was 6/9 with the right eye and 6/5 with the left eye. Both anterior segments and the left fundus were normal. The right fundus showed a superotemporal pigmented choroidal melanoma with a collar of pigment extending within two disc diameters of the fovea (Fig 1). It measured 12.2 mm in diameter and was 5.1 mm thick. The left fundus was treated with proton beam radiotherapy.

Case 2

On 7 November 1999, the patient's 65 year old mother presented to her general practitioner in a different city with a 2 week history of blurred vision in the right eye. She was referred to her primary ophthalmologist who saw her on 11 November 1999, then to our clinic where she was given an appointment on 22 November 1999. Our assessment showed that the visual acuity was 6/36 with the right eye and 6/12+ with the left eye. Both anterior segments and the left fundus were normal. There was a pigmented choroidal tumour inferonasally extending from the disc to the ciliary body, measuring 19.2 mm in diameter and 6.0 mm in thickness (Fig 2). The patient was treated by enucleation.

Neither patient had a history of cutaneous melanoma or atypical naevi, nor could they recall any relevant family history of uveal or other disease. The mother's only sibling and three of four of the daughter's siblings have a normal ocular examination elsewhere.

Comment

We report on the simultaneous presentation of mother and daughter each with uveal melanoma in the right eye with both individuals being seen by their ophthalmologist and by us on the same day. Uveal melanoma is a rare disease, and instances of both parent and child being affected are even rarer. In one series of 4300 patients 17 kindreds were identified in which a first degree relative was also affected. Singh et al reported on a single case of concurrent presentation with father and son presenting within 3 months of each other. Our two
patients presented within only a few hours of each other. The chance of such simultaneous presentation must be extremely remote, but our report demonstrates that coincidence can occur in any disease.

P W Hadden, B E Damato
Liverpool Ocular Oncology Centre, St Paul’s Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK

Correspondence to: Dr P W Hadden, Tennent Institute of Ophthalmology, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK. peterandandy@hotmail.com

Accepted for publication 30 October 2002

References

Relative hypersensitivity in healthy eye by frequency doubling perimetry in patients with severely damaged contralateral eye

Frequency doubling technology (FDT, Humphrey-Zeiss and Welch Allyn, Dublin, CA, USA) has been developed to screen for glaucoma. FDT could detect abnormalities in patients with full visual fields tested by Humphrey field analyser (HFA, Humphrey-Zeiss, Dublin, CA, USA) and nerve fibre layer defects or normal visual fields and large disc cupping. Inversely, FDT did not always detect visual field loss in patients with glaucomatous visual field defects determined by HFA (Fig 1), but it was rare. That was because the ability of FDT to detect glaucomatous visual field loss was limited or for some other reasons. In this study, we presumed that patients with severe damage in one eye had relative hypersensitivity in another eye. Twenty-nine patients (23 men and six women) had one normal healthy eye and one severely damaged eye. Their ages ranged from 18–69 years (mean 51 years). Patients had been examined with threshold c-20 of FDT version 2.6 once. A normal healthy eye meant normal vision (20/20 or better), normal intraocular pressure (less than 21 mm Hg on two occasions), no inflammation, and normal fundus observed clinically. The damaged eye had poor vision (20/200 or worse) or severe visual field defects (mean deviation with FDT less than −6.0 dB). Damage was variously the result of optic nerve lesion by angle recession glaucoma, uveitic glaucoma, or tumour at the orbital apex. Primary open angle glaucoma, optic neuritis or tumour in the brain were excluded, since such conditions usually involve both eyes. As controls, 26 (20 men and six women) normal healthy volunteers were recruited for this study. Their ages ranged from 23 to 70 years (mean 51 years). Patients had been examined with threshold c-20 of FDT version 2.6 once. They had normal vision (20/20 or better), normal intraocular pressure (less than 21 mm Hg), and normal fundus findings. All subjects were examined with threshold c-20 of FDT version 2.6. Mean sensitivity was calculated from all 17 test areas. Mean sensitivity with one normal healthy eye and one severe damaged eye was compared to that in subjects with two normal healthy eyes with Mann-Whitney U test. All results of less than 20% of fixation loss, 20% of false positive, and 33% of false negative were adopted. The research followed institutional guidelines and the tenets of the World Medical Association Declaration of Helsinki. We obtained written informed consent from all patients before their entry in this study.

Eighty results of 55 patients were studied for analysis. One result in patients with two healthy eyes was excluded because of an unreachable result. Twenty-nine eyes with severe damage in one eye had a significantly higher mean sensitivity (mean 30.8 (SE 0.47) dB) in one healthy eye than did both normal healthy eyes (p=0.0065, 28.8 (0.50) dB in 26 normal better eyes and p=0.0005, 27.9 (0.56) dB in 25 normal worse eyes).

Comment
It was interesting that there were 2 dB differences in sensitivity between patients with a normal healthy eye. The reason for eyes with severe damage in one eye having relative hypersensitivity was unclear. One possible explanation was because the pathway detected by FDT is thought to be a magnocellular pathway and a relatively less, complemental mechanism might work in magnocellular pathway.

In conclusion, patients with one severely damaged eye had relative hypersensitivity in one healthy eye. Estimation of such patients should be considered carefully.

Acknowledgements
Supported in part by a grant in aid for scientific research (Dr Fujimoto No 13671822 and Dr Hanawa No 14770942), from Ministry of Education, Culture, Sports, Science and Technology, Japan.

N Fujimoto, D W Zhang, K Minowa, T Hanawa, O Miyashu, E Adachi-Usami
Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine

Correspondence to: Naoya Fujimoto, MD, 1-8-1 Inohana, Chuoku, Chiba 260-8670, Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan; fujimoto@ophthalm.m.chiba-u.ac.jp

Accepted for publication 31 October 2002

References
Solitary choroidal tuberculoma in a patient with chest wall tuberculosis

Tuberculosis has re-emerged as a serious public health problem in industrialised countries. There are several explanations for the increased incidence but it is mainly due to an increase in immunocompromised hosts such as those who are older or with malignancies, those with AIDS, those who are immunosuppressed after transplantation, and the malnourished. However, a choroidal tuberculoma is rare except in cases with human immunodeficiency virus (HIV) infection. We present a case of choroidal tuberculoma in an immunocompetent patient with an extra-pulmonary tuberculoma in the chest wall, which is also rare.

Case report

A 34 year old Filipina woman, who was in good health, complained of a pain in her right lateral chest. Computed tomography scan showed a well defined mass measuring 4 × 4 cm (Fig 1). Cultures of fluid aspirated from the mass showed acid fast bacteria. Polymerase chain reaction demonstrated Mycobacterium tuberculosis DNA in the aspirated fluid. Her sputum had never been positive for tuberculosis. Although the patient had no fever, cough, or anorexia, the mass was diagnosed as extrapulmonary tuberculoma with minimal pulmonary involvement. Anti-tuberculous treatment was started with isoniazid, rifampicin, pyrazinamide, and streptomycin and was reddish. There was a flat retinal fuzzy outline, and the disc had irregular margins just inferior and temporal to the optic disc measured approximately 2 disc diameters

The levels of angiotensin converting enzyme, β2-glucan, titre of antibody for toxoplasmosis, and metastatic tumour from a breast cancer. HIV infection was also ruled out.

The visual acuity in the left eye decreased to 12/200 because of the retinal detachment, and vitreous cells and opacities, and retinal vasculitis were observed. Four to 6 weeks after beginning the anti-tuberculosis therapy, the mass became smaller and visual acuity improved. Although retinal folds were present in the macular lesion after 16 weeks of therapy, the best visual acuity was 20/20 (Fig 3). The cold abscess in the chest wall disappeared within 2 months, with drainage of the fluid and injection of streptomycin.

Comment

There are only a few reported cases of solitary choroidal tuberculoma, and it may present with or without active pulmonary tuberculosis. Ocular tuberculosis commonly presents in the choroid, and reaches the choroid by direct haematogenous spread from a primary infection. The chest wall is also a rare site for tuberculosis, and the co-occurrence of chest wall tuberculosis and choroidal tuberculoma has never been reported with or without HIV infection. Rib tuberculosis was observed in 5% of all cases of bone and joint tuberculosis, and only in 0.1% of all hospital admission for tuberculosis. It is usually secondary to haematogenous spread or, more rarely, due to direct extension of underlying pleural or pulmonary parenchymal disease. In our patient, minimal pulmonary involvement was suspected in the apical lesion, not in chest wall mass lesion. Taken together, the tuberculomas in this patient may be caused by direct haematogenous dissemination. Anti-tuberculosis therapy was effective for both tuberculomas.

In conclusion, we report a rare case of choroidal tuberculoma with chest wall tuberculosis. With the re-emergence of tuberculosis, ophthalmologists should be aware that solitary choroidal tuberculoma as well as extrapulmonary tuberculosis can occur in immunocompetent individuals.

K Ohita, Y Yamamoto, J Arai, Y Komurasaki, N Yoshimura
Department of Ophthalmology, Shinshu University School of Medicine, Matsumoto, Japan

Correspondence to: Kouichi Ohita, MD, PhD, Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan; kohita@shp.md.shinshu-u.ac.jp

Accepted for publication 9 November 2002

References


Giant neurosensory detachments associated with disciform lesions in neovascular age related macular degeneration

Age related macular degeneration (AMD) is the leading cause of blindness among the population over 65 years of age in Europe and North America. Neovascular AMD, which is characterised by choroidal neovascularisation, often leads to severe central vision loss. Choroidal neovascularisation may lead to
A 69 year old white man presented to the Vitreoretinal Division at the Wilmer Ophthalmological Institute for evaluation of his macular degeneration. He was diagnosed with macular degeneration by an outside ophthalmologist in 1992. He reported slowly worsening vision in both eyes over many years. He denied any recent changes in his vision. Family history was significant for AMD affecting his father, sister and brother. He denied history of ocular trauma, surgery, or laser.

On ophthalmological examination, the best corrected visual acuity was “hand movement at 4 feet” in the right eye and 4/200 in the left eye. There was no relative afferent pupillary defect. Extraocular movements were full in each eye. Anterior segment examination was remarkable for moderate nuclear sclerotic and cortical cataracts in each eye. Extended ophthalmoscopy showed cup to disc ratio as 0.3 without evidence of optic nerve head oedema or pallor. The maculae showed disciform lesions in both eyes with overlying large and bullous neurosensory detachments.

Successful photodynamic therapy for subretinal neovascularisation due to Sorsby’s fundus dystrophy: 1 year follow up

Sorsby’s fundus dystrophy (SFD) is a rare but severe autosomal dominant disease. Clinically it is characterised by severe central visual loss, mainly due to submacular choroidal neovascularisation (CNV) during the fifth decade of life. Blindness therefore occurs during the patient’s most productive years of employment. We report a case of successful treatment of CNV in SFD with photodynamic therapy (PDT) and verteporfin.

Case report

A 40 year old white man (occupation photographer) presented in 1999 with sudden blurring and distortion of vision in the right eye. Visual acuity was 6/6 in the right eye and 6/4 in the left. Funduscopics and fundus fluorescein angiogram (FFA) demonstrated a large subfoveal CNV. This was deemed unsuitable for laser photocoagulation owing to its location and size. Subsequently, acuity in the right eye deteriorated to 3/60 with the formation of a disciform macular scar. Standard flash electroretinography (ERG) was normal, while dark adapted ERG was abnormal. Family history revealed that his mother and paternal grandmother went “blind” in their 50s. The patient’s cousin had also suffered from recent vision loss. A clinical diagnosis of SFD was made based on the patient’s age, family history, and retinal appearance. This was confirmed by molecular genetic assessment. Restriction digest analysis (using XhoI) showed that both the patient and his affected cousin were heterozygous for the Ser181Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) gene.

In 2001 the patient reported visual disturbance in his left eye. Visual acuity in the left eye had decreased to 6/36. FFA revealed a left extrafoveal, predominantly classic, CNV (Fig 1). It was known that submacular CNV in SFD responded poorly to conventional argon laser treatment, so we elected to undertake photodynamic therapy (PDT) with verteporfin. The protocol used for treatment was as previously described.

Further PDT treatments were applied to the left macula at 3, 6, and 12 months. These supplemental treatments were prompted by fresh leakage seen on FFA. At 1 year, a small subretinal scar was seen at the site of the original CNV and some leakage was noted at 4 months. The patient’s visual acuity was 6/9 in the left eye with PDT treatment. Further follow up is required to determine if neovascularisation has regressed or persisted.
the inferonasal edge of this scar (Fig 2). Further PDT treatment is planned for this. Visual acuity in his left eye improved from 6/36 to 6/12 and this has been maintained for the 1 year of follow up.

Comment
SFD was first described by Sorsby in 1949. Mildly affected patients suffer colour vision deficits and night blindness. In such patients, mid-peripheral drusen are often seen. Histologically, a confluent, lipid containing layer is seen deposited within the inner layer of Bruch’s membrane. Consistently, in the fourth to fifth decade of life affected patients suffer sudden, severe vision loss due to CNV. A few experience more gradual vision loss due to macular atrophy. All patients invariably progress to vision loss sufficient for blind registration.

Despite some evidence to suggest improvement in night blindness with vitamin A supplements by far the most significant visual deficit in SFD relates to the complications of CNV. Effective treatment needs to be devised for this. Unlike age related macular degeneration, even if the CNV in SFD is extrafoveal, argon laser therapy is ineffective. Also, CNV natural history in age related macular degeneration can result in a variable final visual acuity. In SFD, however, visual prognosis after CNV, particularly when associated with the TIMP3 Ser181Cys mutation, is always very poor. It is particularly noteworthy therefore that 1 year after treatment, visual acuity has improved and has been maintained at 6/12 when acuity would be expected to have declined to 6/60 or less. Significantly, this has allowed the patient to continue in his career as a photographer.

This is the first report suggesting that treatment may limit severe visual deficit in an SFD patient and for an extended period. Photodynamic therapy with verteporfin should therefore be considered in other SFD patients when they suffer CNV.

S C Wong, K C S Fong, N Lee, K Gregory-Evans
Western Eye Hospital, Marylebone Road, London NW1 5YE, UK

C Y Gregory-Evans
Department of Cell and Molecular Biology, Faculty of Medicine, Imperial College, Exhibition Road, London, UK

Correspondence to: Mr Kevin Gregory-Evans, Western Eye Hospital, Marylebone Road, London NW1 5YE, UK, k.gregory-evans@ic.ac.uk

Accepted for publication 27 November 2002

References

Association of HLA type and Mooren’s ulcer in Chinese in Taiwan
We read with interest the article by Taylor et al., suggesting a possible association between HLA-DR17(3) and/or DQ2 and susceptibility to Mooren’s ulcer on the basis of cases collected globally, though none were Chinese. We have collected HLA data on cases of peripheral ulcerative keratopathy and investigated the genetic relation between Mooren’s ulcer and HLA type in Chinese people.

In total, eight patients with non-infectious peripheral destructive corneal ulcer were treated in our referral clinic. Full systemic and ocular examinations were performed to diagnose Mooren’s ulcer. A laboratory examination to rule out the possible rheumatological and infectious causes, included complete blood count with platelet count, serum complement fixation, circulating immune complexes, antinuclear antibodies, rheumatoid factor, anti-neutrophil cytoplasmic antibodies, erythrocyte sedimentation rate, C reactive protein, rapid plasma reagent/fluorescent treponemal antibody absorption test, antibodies of herpes simplex, herpes zoster, and Toxoplasma, hepatitis B and C tests, liver function tests, blood urea nitrogen and creatinine, fasting blood sugar, urinalysis, chest x ray, sinus x ray, and kidney, ureter, and bladder x ray (KUB) study. Complete ocular evaluations included slit lamp microscopy, conjunctival and corneal swabs for cultures of possible infective agents, and tear function tests such as Schirmer’s test and tear break up time (TBUT). All of our patients were Chinese and two were given the diagnosis of Mooren’s ulcer. Both patients had a normal other eye, and were otherwise healthy, except for previous hepatitis B infection, which is very common (up to 90%) in those more than 40 years old) in Taiwan.

Case report
Patient 1
A 67 year old woman presented with a 3 week history of a painful, tearing and a photophobic right eye in June 2002. Slit lamp biomicroscopy revealed an inferior peripheral corneal ulcer and adjacent conjunctival injection of her right eye. This crescent shaped ulcer caused thinning to 50% of the corneal thickness, thereby weakening the central edge of the inferior peripheral cornea. In addition,
overlying epithelial defect was noted by fluorescein staining.

**Patient 2**

A 60 year old woman was referred for a painful, red right eye with incipient peripheral corneal perforation of 3 months’ duration. She reported a history of extracapsular cataract extraction of her right eye 8 months before, in November 2001. On examination, there was marked thinning of the right superior cornea from 10 to 2:30 o’clock with pannus and an infiltrated leading edge. Within the marginal ulcer, around 90% of the areas was thinned to 10% of the corneal thickness. Rheumatological evaluation was normal. This ulcer perforated 4 days after admission and emergency repair with multilayered amniotic membrane covered with a conjunctival graft was performed smoothly. Afterwards the destruction of peripheral corneal stroma ceased to progress and the anterior chamber was reformed 3 days after surgery.

Blood samples of these patients were obtained and tested for HLA-A, B, C, DR, and DQ typing by the polymerase chain reaction (PCR). Specific sequence primer (PCR-SSP) low resolution method. HLA-A, B, C, DR were tested using One Lambda (One Lambda Inc, Canoga Park, CA, USA) Micro SSP genetic HLA class I and II typing trays. HLA typing was tested by using Dynal all set typing trays (Dynal Biotech Ltd, Wirral, UK). The HLA types of two Mooren’s ulcer patients are HLA-DR17(3) and DQ2 positive, which is still higher than in ethnically matched control populations. In Craig’s study, we find that 11 of 14 (78.5%) patients with Mooren’s ulcer are HLA-DR17(3) and DQ2 positive, which is still higher than in ethnically matched control populations. In Craig’s article, 100% of non-white Mooren’s ulcer patients are HLA-DR17(3) and DQ2 positive, but if our patients are included in this assessment, the frequency decreases to 90% of non-white patients.

Another interesting finding was the increased frequencies of HLA-DQ5. In the Mooren’s ulcer group, HLA-DQ5 was found in 30% patients, whether or not our data and Craig’s are considered as a whole. The HLA-DQ5 antigen frequencies are 21–25% in Chinese people are 1–8% and 7–15%, respectively. If we combine the data of our two female Chinese Mooren’s ulcer patients with those of patients in Craig’s study, we find that 11 of 14 (78.5%) patients with Mooren’s ulcer are HLA-DR17(3) and DQ2 positive, which is still higher than in ethnically matched control populations. In Craig’s article, 100% of non-white Mooren’s ulcer patients are HLA-DR17(3) and DQ2 positive, but if our patients are included in this assessment, the frequency decreases to 90% of non-white patients.

**Comment**

According to Craig’s report, 10 of 12 Mooren’s ulcer patients (83%) were HLA-DR17(3) and/or HLA-DQ2 positive. According to published population studies, the HLA-DR17(3) antigen frequencies are 4–19% in India, 10–20% in black South Africans, and 23% in white northern Europeans. The HLA-DQ2 antigen frequencies are 36–45% in India, 17–19% in black South Africans, and 33% in white northern Europeans. These findings suggest predisposition of HLA-DR17(3) and HLA-DQ2 might have some significant association with susceptibility to Mooren’s ulcer.

The HLA-DR17(3) and DQ2 antigen frequencies for Chinese people are 1–8% and 7–15%, respectively. If we combine the data of our two female Chinese Mooren’s ulcer patients with those of patients in Craig’s study, we find that 11 of 14 (78.5%) patients with Mooren’s ulcer are HLA-DR17(3) and DQ2 positive, which is still higher than in ethnically matched control populations. In Craig’s article, 100% of non-white Mooren’s ulcer patients are HLA-DR17(3) and DQ2 positive, but if our patients are included in this assessment, the frequency decreases to 90% of non-white patients.

Another interesting finding was the increased frequencies of HLA-DQ5. In the Mooren’s ulcer group, HLA-DQ5 was found in 30% patients, whether or not our data and Craig’s are considered as a whole. The HLA-DQ5 antigen frequencies are 21–25% in Chinese people, 13–22% in black South Africans, 10–32% in white northern Europeans, and 10–21% in Chinese. Therefore, our data support the possible linkage of HLA-DR17(3), HLA-DQ2 gene with Mooren’s ulcer proposed by Craig’s article, and suggest HLA-DQ5 might be another candidate gene of HLA associated with Mooren’s ulcer.

**References**


**Table 1** HLA class I and II types of two Mooren’s ulcer patients

<table>
<thead>
<tr>
<th>HLA typing</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Antigen frequencies (% of Chinese in Taiwan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-A</td>
<td>A2</td>
<td>28.82–32.81</td>
<td>A11 18.00–36.06</td>
</tr>
<tr>
<td></td>
<td>A24</td>
<td>14.88–19.76</td>
<td>A33  8.72–11.56</td>
</tr>
<tr>
<td>HLA-B</td>
<td>B46</td>
<td>8.55–17.23</td>
<td>B54 1.61–4.32</td>
</tr>
<tr>
<td></td>
<td>B61</td>
<td>2.71–3.77</td>
<td>B75 1.64–5.40</td>
</tr>
<tr>
<td></td>
<td>BW6</td>
<td>1.64–5.40</td>
<td>BW6* 1.64–5.40</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>DR4</td>
<td>11.69–15.41</td>
<td>DR9 13.56–16.36</td>
</tr>
<tr>
<td></td>
<td>DR16</td>
<td>1.31–5.44</td>
<td>DR16 1.31–5.44</td>
</tr>
<tr>
<td></td>
<td>DR17(3)</td>
<td>0.98–8.37</td>
<td>DR51† 0.98–8.37</td>
</tr>
<tr>
<td></td>
<td>DR53‡</td>
<td>0.98–8.37</td>
<td>DR53‡ 0.98–8.37</td>
</tr>
<tr>
<td>HLA-DQ</td>
<td>DQ2</td>
<td>7.51–15.66</td>
<td>DQ4 5.03–9.88</td>
</tr>
<tr>
<td></td>
<td>DQ5</td>
<td>10.60–21.50</td>
<td>DQ5 4.31–13.06</td>
</tr>
<tr>
<td></td>
<td>DQ9</td>
<td>4.31–13.06</td>
<td>DQ9 4.31–13.06</td>
</tr>
</tbody>
</table>

*BW6 associations: B46, B54, B61, B75; †DR51 associations: DR15, DR16, DR1; ‡DR53 associations: DR4, DR7, DR9.

**Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia**

We report a case of corneal endothelial deposits in a patient positive for human immunodeficiency virus (HIV) who had received rifabutin prophylaxis for Mycobacterium avium complex bacteraemia.

**Case report**

A 50 year old man was referred to the corneal clinic with bilateral scattered endothelial deposits. He was asymptomatic at the time of presentation.

His history indicated that he had been HIV positive since 1992 and had been commenced on treatment in 1995. Since then he had suffered from tuberculosis and pneumonia but there was no history of any eye problems.

His systemic health was currently good and his CD4 count was 540 cells ×10³. His ophthalmic history revealed loss of vision in the right eye in 1986 following an episode of herpes zoster in this eye.

On examination his right visual acuity was no perception of light and his left visual acuity was 6/9. Both eyes were white. Corneal examination revealed bilateral endothelial deposits, scattered through out the cornea, stellate in the middle but more confluent in the periphery (Fig 1).

There was no associated uveitis. The intraocular pressures were within normal limits. There were posterior synechiae and a white cataract in the right eye, which precluded any fundal view. The left eye had a clear lens and fundal examination was entirely normal.

A detailed history of his medications indicated that he had received rifabutin for 2 years but had been off this treatment for 18 months before his referral to the eye clinic.

**Figure 1** Example of bilateral endothelial deposits.

C-K Liang, K-H Chen, W-M Hsu
Department of Ophthalmology, Taipei Veterans General Hospital, 201, Shih-Pai Road, Section II, and National Yang-Ming University, Taipei, Taiwan, 11217, ROC

K-H Chen
Division of Medical Engineering, National Health Research Institute, Taipei, Taiwan 114, ROC

Accepted for publication 29 November 2002

Correspondence to: Ko-Hua Chen, MD, Department of Ophthalmology, Taipei Veterans General Hospital, 201, Shih-Pai Road, Section II, Taipei, Taiwan 11217, ROC; kchen@vghtpe.gov.tw

www.bjophthalmol.com
Serial photography over the past 9 months has not shown any change in the appearance of these deposits.

Comment
Rifabutin is used to prevent Mycobacterium avium complex (MAC) disease in patients with HIV and CD4 counts of less than 100 cells × 10^6. Rifabutin causes inhibition of DNA-dependent RNA polymerase in sensitive strains of Escherichia coli and Bacillus subtilis. However, its mode of action against M avium is unclear. It has been associated with uveitis, which may be difficult to differentiate from other causes of uveitis in patients with AIDS. Uveitis is unusual at the recommended oral dosage of 300 mg/day, but becomes common as the total daily dose approaches 1 g.

Corneal endothelial deposits secondary to treatment with rifabutin have been reported in children positive for HIV. The deposits are usually bilateral and initially peripheral and stellate. Of interest is the fact that these deposits occur without any associated uveitis. They increase in number with continued administration of rifabutin but appear not to be sight threatening. This also demonstrates that these endothelial deposits do not appear to resolve upon termination of rifabutin therapy in the short to medium term. A longer period of observation is required to determine if these deposits alter in the long term.

B Golchin, KMcClellan
Sydney Hospital and Sydney Eye Hospital, PO Box 1614, Sydney NSW 2001, Australia

Correspondence to: Kathleen McClellan, Sydney Hospital and Sydney Eye Hospital, PO Box 1614, Sydney NSW 2001, Australia; kathy@eye.usyd.edu.au

Accepted for publication 30 November 2002

References

Corneal ectasia following deep lamellar keratoplasty
Keratoconus is a bilateral non-inflammatory corneal ectasia with an incidence of approximately one per 2000 in the general population. Contact lenses are the most common treatment. When contact lenses fail, a surgical approach is necessary for visual rehabilitation. Penetrating keratoplasty has been the traditional and most common mode of treatment and has excellent results. However, more recently, deep lamellar keratoplasty (DLK) is gaining popularity as an alternative option for the surgical management of keratoconus. It has obvious advantages in that endothelial rejection is rare and it is essentially an extracocular procedure. Recurrent keratoconus following penetrating keratoplasty is rare but has been described. We report on the first case of recurrent ectasia following deep lamellar keratoplasty supported by clinical and histological evidence.

Case report
A 38 year old chronic schizophrenic male was referred to the anterior segment clinic with advanced bilateral keratoconus. He had previously been treated with hard contact lenses. His condition had deteriorated over the years and he was now keen on surgical intervention. On examination, visual acuity was counting fingers in both eyes with no improvement with trial lens. Anterior segment examination revealed bilateral advanced cones with subepithelial scarring. Fundal examination was unremarkable.

The patient underwent uneventful right lamellar keratoplasty with lyophilised corneal tissue under general anaesthetic. The left eye had the same procedure with intraoperative Botox injection to the upper lid 1 year later. Again, the procedure was uneventful but postoperatively, he developed a persistent central epithelial defect which later became infected. There was no improvement in the patient’s condition despite intensive antibiotics and the patient underwent an emergency left lamellar keratoplasty 1 month later. Twelve months postoperatively, corrected VA had improved to 6/60 right eye and 6/18 left eye. Topographical data and refraction were not done at this time and he was noted to have bilateral lens opacities.

Three years later the patient was reviewed with decreased vision in both eyes. On examination, uniconical visual acuity was counting fingers and hand movements in the right and left eye, respectively. Anterior segment examination revealed bilateral central subepithelial corneal opacities more pronounced in the left eye with severe apical thinning (Fig 1). He had bilateral nuclear cataracts more marked in the right eye. Corneal topography demonstrated marked inferior steepening in the left eye consistent with keratoconus (Fig 2). A repeat DLK was performed on the left eye and histology from the second grafted corneal button showed degenerative thinning consistent with ectasia. The original host tissue in comparison revealed breaks in Bowman’s membrane which is typical of keratoconus (Fig 3). At his last clinic visit 1 month later, having undergone bilateral cataract extractions and IOL implantation in the preceding year, his visual acuity was 6/9–2 right eye with +3.25/−8.00×140 correction and 6/9 left eye with +4.00/−4.50×180.

Comment
Lamellar keratoplasty (LK) has been an established procedure for corneal pathology for over a 100 years. Advances in surgical techniques such as deep lamellar anterior keratoplasty have expanded the application of lamellar surgery and have achieved visual results approaching those of penetrating keratoplasty while reducing the rate of rejection and improving the long-term graft stability. The procedure can be defined as the excision of superficial stromal layers. A number of techniques have been used for dissection of the stroma such as air, viscoelastic, and fluid injection. The entire stroma can be completely excised so that only Descemet’s membrane and endothelial cells remain.

Studies have shown that in deep lamellar keratoplasty, endothelial rejection reaction is rare with cell counts being maintained for a longer period. This confers obvious advantages over penetrating keratoplasty in the treatment of keratoconus. However, it is still a relatively new procedure and is technically more challenging.

There have been a few cases in the literature of recurrent keratoconus following penetrating keratoplasty successfully treated with regrafting. In all these cases, the pathogenesis of this complication was unclear. In our patient, ectasia recurred in the left eye 3 years after deep lamellar keratoplasty and this was confirmed both clinically and histologically. Donor factors include the possibility of ectatic disease which may have been missed or remained subclinical throughout the donor’s life. New screening methods utilising the Orbscan are being explored looking at the topography of donor corneas that could
Another consideration is that the cryo-osthade corneal lenticule used at the time of repeat surgery may have been inherently thin as the procedure was done as an emergency. Adequate preparation of the donor tissue is therefore necessary before surgery. The inflammatory pathways activated following the first DLK failure due to infection, in particular the metalloproteinase system (gelatinolytic activity of stromal collagenase (matrix metalloproteinase-1 (MMP-1)), may play an important part through thinning of the stromal tissue.

These lenticules are devoid of keratocytes; invasion of the graft by host keratocytes, which may be metabolically prone to producing abnormal corneal architecture, may contribute to ectasia.

In summary, we have reported the first case of recurrent ectasia in a relatively new treatment option—deep lamellar keratoplasty for keratoconus. Protection of the lamellar graft from infection and inflammation is important in order to obtain the best visual potential. Preoperative and postoperative data such as refraction, topography, and pachymetry are vital in monitoring progression of these patients. As lamellar surgery becomes increasingly popular it is important to recognise such late complications which may require further surgical intervention in the future.

N Patel
Retinal Research Unit, Department of Ophthalmology, Kings College Hospital, East Dulwich Grove, Dulwich, London SE22 8PT, UK

A Mearza, C K Rostron
Department of Ophthalmology, St George’s Hospital and School of Medicine, University of London, Blackshaw Road, Tooting, London SW17 0QT, UK

References

Figure 1 Slit lamp examination of opacified IOL

Figure 3 Histopathology slides of the original host keratoconic cornea showing apical thinning and subepithelial scarring in the low magnification (A) High magnification with Jones stain shows disruption of Bowman’s membrane (B). In comparison, the deep lamellar keratoplasty corneal button shows apical thinning (C) but no disruption of Bowman’s membrane (D). Low power (haematoxylin and eosin stain) shows disruption of Bowman’s membrane (D). In comparison, the deep lamellar keratoplasty corneal button shows apical thinning (C) and subepithelial scarring in the low magnification (A) High magnification with Jones stain shows disruption of Bowman’s membrane (B).
Figure 2. SEM examination of explanted IOL showing 5 μm thick degraded layer of outer surface. (A) ×2000, (B) ×7000.

Isolated foveal retinoschisis as a cause of visual loss in young females

Foveal or macular retinoschisis is an uncommon retinal disorder, usually seen in patients affected with generalised retinal disease such as X linked retinoschisis,^1^ Goldmann-Favre syndrome,^2^ and enhanced S-cone syndrome. There have been a handful of previous reports of patients exhibiting foveal retinoschisis in whom there appeared to be limited concomitant peripheral retinal disease,^3^ suggesting the existence of a distinct disorder. We report the clinical findings in four female patients presenting with a reduction in central acuity and exhibiting isolated bilateral foveal retinoschisis, and investigations including scanning laser ophthalmoscopy (SLO) autofluorescence imaging, optical coherence tomography (OCT), and electrophysiology.

Case reports

Case 1
A 17 year old girl presented with bilateral reduction in central vision. With refraction (+0.50 DS right, +0.25 DS left) her visual acuity was 6/18. On examination the only abnormal finding was thickening of the neurosensory retina at the fovea with a radial pattern of striae bilaterally. There was no leakage suggestive of macular oedema on fluorescein angiography.

Cases 2 and 3
Female dizygotic twins 19 years of age both reported a mild non-progressive reduction in

References

1. Ridley NHL. Artificial intraocular lenses after cataract extraction. St Thomas Hospital Reports 1951;7:12–14.
in inheritance. It is of interest that all eight cases are female. This might represent a chance finding (this is unlikely: p = 0.016, considering the identical twins in the report by Lewis et al as one case), a real underlying sex difference in the prevalence of this rare condition, or the under-reporting of similar male cases as a result of their assignment to a diagnosis of XLRS. There are a few other cases in the literature demonstrating a similar foveal appearance with minimal peripheral changes \textsuperscript{4,5,7} which may be manifesting a different disorder. It is very difficult to predict the long term prognosis for our patients, as such cases are rare and longitudinal data are unavailable. Future genetic analysis, such as screening for novel mutations in NR2E3, the gene responsible for enhanced S-cone syndrome, may shed light on the aetiology of this rare disorder.

S A Kabanarou, G E Holder, A C Bird, A R Webster
Moorfields Eye Hospital, London, UK

S A Kabanarou, A C Bird, A R Webster
Institute of Ophthalmology, London, UK

P E Stanga
St Paul’s Eye Unit, Royal Liverpool University Hospital, UK

S Vickers
The Sussex Eye Hospital, Brighton, UK

B A Harney
Gloucestershire Hospitals NHS Trust, UK

Correspondence to: Andrew R Webster, MD, Institute of Ophthalmology, Department of Molecular Genetics, 11–43 Bath Street, London EC1V 9EL, UK; andrew.webster@ucl.ac.uk

Accepted for publication 22 November 2002

References


Figure 1 A prototype Zeiss confocal scanning laser ophthalmoscope (SLO) recorded autofluorescence images using argon laser blue light and a broadband pass barrier filter with a short wavelength cut off at 521 nm. Single line bilaminar scans of the macular retina were performed using the OCT 2000 scanner (Zeiss Humphrey Instruments, San Leandro, CA, USA).
### Monitoring cataract surgical outcomes

The latest issue of *Community Eye Health* (No 44) discusses the monitoring of cataract surgical outcomes in the Third World. For further information please contact: Journal of Community Eye Health, International Centre for Eye Health, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7608 6910; fax: +44 (0)20 7250 3207; email: eyeresource@ucl.ac.uk; website: www.jceh.org.uk). Annual subscription (4 issues) UK£25/ US$40. Free to workers in developing countries.

### International Centre for Eye Health

The International Centre for Eye Health has published a new edition of the *Standard List of Medicines, Equipment, Instruments and Optical Supplies* (2001) for eye care services in developing countries. It is compiled by the Task Force of the International Agency for the Prevention of Blindness. Further details: Sue Stevens, International Centre for Eye Health, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7608 6910; email: eyeresource@ucl.ac.uk).

### Second Sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. Details can be found at the charity’s website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

### Surgical Eye Expeditions International

Volunteer ophthalmologists in active surgical practice are needed to participate in short term, sight restoring eye surgery clinics around the world. Contact: Harry S Brown, Surgical Eye Expeditions International, 27 East De La Guerra, C-2, Santa Barbara, CA 93101-9858, USA (tel: +805 963 3303; fax: +805 963 3564; email: hsbrown.md@cox.net or seeintl@seeintl.org; website: www.seeintl.org).

### MSc course in Community Eye Health

The International Centre for Eye Health is offering a full time MSc course in Community Eye Health from 29 September 2003 to 19 September 2004. The course is not clinical and is specifically for eye health professionals wanting to work in the field of community eye health. The course is designed in keeping with the aims, priorities, and strategies of Vision 2020—the Right to Sight. The course costs £3939 for home students and £14110 for overseas students. Further information: The Registry, 50 Bedford Square, London WC1B 3DP, UK (tel: +44 (0)20 7927 2239; fax: +44 (0)20 7323 0638; email: Adrienne.Burrough@lshtm.ac.uk; website: www.lshtm.ac.uk).

### Institute of Ophthalmology: Professor Alan Bird’s 65th Birthday Meeting

The Institute of Ophthalmology is holding a meeting to celebrate Professor Alan Bird’s 65th Birthday on 10–11 July 2003, at The Beveridge Hall, Senate House, University of London, Malet Street, London. Session one on Retinal Dystrophies will be chaired by Professor Tony Moore and session two on The Ageing Macula will be chaired by Professor Steve Ryan. It is expected that CME credit will be awarded. Admission is free. Places for the meeting are limited and booking is essential. There will also be a dinner held on Thursday evening for guests and partners, the cost is £40 (US$62). Further details: Miss Laura Short, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK (register on the website: www.ucl.ac.uk/ioo).

### Glaucome Society 24th Annual Meeting and Dinner

The Glaucome Society 24th Annual Meeting and Dinner will take place on 20 November 2003, from 8:30 am to 5:00 pm at The Royal College of Physicians, London, UK. Further details: Ms Janet Flowers (email: glaucos@ukeire.freeserve.co.uk).

---

While the main content of the image is text, there are also some tables and figures. For instance, the table below shows the results of a study on cataract surgical outcomes:

<table>
<thead>
<tr>
<th>Case</th>
<th>Scotopic Rod</th>
<th>Maximal</th>
<th>30 Hz Photopic</th>
<th>200 ms Stim PERG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>400 µV</td>
<td>500 µV</td>
<td>600 µV</td>
<td>700 µV</td>
</tr>
<tr>
<td>2</td>
<td>450 µV</td>
<td>550 µV</td>
<td>650 µV</td>
<td>750 µV</td>
</tr>
<tr>
<td>3</td>
<td>500 µV</td>
<td>600 µV</td>
<td>700 µV</td>
<td>800 µV</td>
</tr>
<tr>
<td>4</td>
<td>600 µV</td>
<td>700 µV</td>
<td>800 µV</td>
<td>900 µV</td>
</tr>
</tbody>
</table>

**Figure 2.** Full field electroretinogram (ERG) and pattern ERG were recorded using standardised methods according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards. Long duration photopic stimulation was performed to separate ON and OFF photopic pathways.
Successful photodynamic therapy for subretinal neovascularisation due to Sorsby’s fundus dystrophy: 1 year follow up

S C Wong, K C S Fong, N Lee, K Gregory-Evans and C Y Gregory-Evans

*Br J Ophthalmol* 2003 87: 796-797
doi: 10.1136/bjo.87.6.796

Updated information and services can be found at:
http://bjo.bmj.com/content/87/6/796

**References**

This article cites 10 articles, 4 of which you can access for free at:
http://bjo.bmj.com/content/87/6/796#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/